Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18456259 | 0.86 | TGM2 (0.40) | TGM2CYP19A1THRBATMTDP1 | |
| SCHEMBL14449399 | 0.84 | TGM2 (0.36) | TGM2CYP19A1THRBATMTDP1 | |
| SCHEMBL25141032 | 0.79 | TGM2 (0.38) | TGM2CYP19A1THRBATMTDP1 | |
| SCHEMBL19558477 | 0.78 | THRB (0.34) | TGM2THRBATMTDP1L3MBTL1 | |
| SCHEMBL24554358 | 0.78 | ELANE (0.34) | CYP19A1THRBATMTDP1L3MBTL1 | |
| SCHEMBL19266440 | 0.77 | THRB (0.33) | TGM2THRB | |
| SCHEMBL22504926 | 0.76 | TGM2 (0.36) | TGM2THRBATMTDP1L3MBTL1 | |
| SCHEMBL19917284 | 0.76 | TGM2 (0.36) | TGM2THRBATMTDP1L3MBTL1 | |
| SCHEMBL19322527 | 0.76 | TGM2 (0.41) | TGM2CYP19A1THRBATMTDP1 | |
| SCHEMBL20102792 | 0.75 | TGM2 (0.35) | TGM2THRBATMTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639338-B1 | Compound producing method, and compound | KUREHA CORPORATION (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20180057429-A1 | SYSTEM AND METHOD FOR PREPARING AROMATIC DERIVATIVE | LCY Chemical Corp. (TW) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057429-A1 | SYSTEM AND METHOD FOR PREPARING AROMATIC DERIVATIVE | AHR, BLVRB, RARB | TGM2 3890/4885CYP19A1 389/4885THRB 450/4885 |
| US-11639338-B1 | Compound producing method, and compound | CA7, CYP3A7, GANC | TGM2 793/4885CYP19A1 495/4885THRB 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.